These data, along with the previously reported efficacy data that showed noninferiority of MYL-1501D, demonstrate the similarity of MYL-1501D to reference insulin glargine in patients with type 1 diabetes and patients with type 2 diabetes and support the use of MYL-1501D as a basal insulin analogue for the treatment of diabetes. Here, INS is linked to type 1 diabetes mellitus.